Memphasys Ltd has released a press release.
Felix Trial Confirms Best-in-Class Performance
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Memphasys
- Half Yearly Report and Accounts
- Extension of Convertible Notes
- Felix Data lock complete and regulatory submission commenced
- Leading Brazilian Andrology Clinic to test Felix System
- Felix Clinical Trial complete, Data Lock expected in 2 weeks
Later from Memphasys
- RoXsta offers Effective Oxidative Stress Measurem't 4 Cattle
- Pause in Trading
- $1.275M Placement to Accelerate Commercial Rollout
- MEM Successfully trials RoXsta Mega Cell High-Throughput
- CE Mark Lodged for Felix to Expand Global Access
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys